IRA Drug Price Negotiation Expands to 15 More Products, Including High-Spend Diabetes and Behavioral Health Drugs

CMS has selected 15 additional Part D drugs for Medicare price negotiation under the Inflation Reduction Act, representing $41 billion in Part D spending and affecting 5.3 million beneficiaries. The list includes high-cost medications for diabetes, behavioral health conditions, and cancer that are also commonly covered in Medicaid managed care formularies. While the negotiation applies to Medicare, the pricing pressure and manufacturer strategies could influence Medicaid rebate structures and drug access in managed care plans that cover dual-eligible populations.

Pharmacy

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere